Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Exela Pharma Sciences LLC
483
•Exela Pharma Sciences LLC•November 21, 2014

Exela Pharma Sciences LLC – FDA 483, Nov 21, 2014

Record Details

On November 17-21, 2014, the FDA inspected Exela Pharma Sciences, LLC, an outsourcing facility located at 1325 William White Place, Lenoir, NC. The inspection, conducted by Consumer Safety Officers Noreen Muniz and Brett Weed, identified deficiencies in procedures designed to prevent microbiological contamination of sterile drug products.

Specifically, media fills, as per procedure QA012-02, lacked documented evidence to justify the number and frequency of simulated interventions, did not include simultaneous routine activities, and failed to fully document media temperature before filling.

A smoke study video (document# 2010-PQ-123, 08/19/2010) for the Grade A Sterile Area Filling Machine was deemed inadequate. It used limited smoke, did not confirm uni-directional flow within the filling line, omitted operator interventions (especially simultaneous or line set-up activities), failed to follow smoke patterns near wall air returns, and showed operators performing slow movements inconsistent with routine operations.

Furthermore, operators did not consistently follow procedure OP006-02, "Behavior in Manufacturing Clean Rooms." Observations on November 17, 2014, included fast, uncontrolled movements, abrupt opening of enclosures, and simultaneous interventions. A July 2014 media fill video showed operators moving with uncontrolled movements, talking, blocking air returns, and performing non-controlled interventions in the Grade

Company
Exela Pharma Sciences LLC
Inspection date
November 21, 2014
Product type
Drugs
Office
Atlanta District Office
People
  • Noreen Muniz (Investigator)
  • Brett Weed (Consumer Safety Officer)
View Company Profile

ID · d66b0c30-18ff-483c-9e48-0cd7c7c061c7

Violation Codes1
FD&C Act 801(a)(3)

Full citation text and observation details available on the Dashboard.

Other documents for Exela Pharma Sciences LLC
  • WARNING_LETTER - 2024-11-15November 15, 2024
  • 483 - 2024-11-04November 4, 2024
  • EIR - 2019-10-22October 22, 2019
  • EIR - 2019-07-18July 18, 2019
  • 483 - 2019-07-18July 18, 2019

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Exela Pharma Sciences LLC
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.